Stevens First Principles Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-400	Closed	-$42K	–	208
2015 Q3	$42K	Buy	400 +200	+100%	+$25.7K	0.03%	124
2015 Q2	$25K	Hold	200	–	–	0.02%	165
2015 Q1	$24K	Sell	200 -300	-60%	-$35.9K	0.02%	155
2014 Q4	$59K	Sell	500 -100	-17%	-$11.3K	0.04%	128
2014 Q3	$67K	Sell	600 -400	-40%	-$38.1K	0.04%	134
2014 Q2	$95K	Sell	1,000 -300	-23%	-$21K	0.05%	120
2014 Q1	$92K	Buy	1,300 +500	+63%	+$39.6K	0.06%	115
2013 Q4	$59K	Buy	800 +600	+300%	+$41.8K	0.04%	134
2013 Q3	$15K	Sell	200 -100	-33%	-$7.96K	0.01%	168
2013 Q2	$24K	Buy	+300	New	+$22.1K	0.02%	157

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens First Principles Investment Advisors's VRTX Position: Q4 2015 in Review

Stevens First Principles Investment Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2015, closing a stake of 400 shares — an estimated $42K sold.

Stevens First Principles Investment Advisors first reported a position in VRTX in Q2 2013 and held it in 10 quarters. The position peaked at $95K in Q2 2014. 518 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

Stevens First Principles Investment Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Stevens First Principles Investment Advisors sold 400 Vertex Pharmaceuticals shares in Q4 2015, an estimated $42K.
Stevens First Principles Investment Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Stevens First Principles Investment Advisors's Vertex Pharmaceuticals position peaked at $95K in Q2 2014.
518 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Stevens First Principles Investment Advisors's 13F filing for Q4 2015, filed 29 Jan 2016.